MiNK Therapeutics Reports Complete Remission in Metastatic Testicular Cancer Patient

MiNK Therapeutics has reported a landmark case of complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer treated with their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, combined with nivolumab. Despite the patient having failed multiple prior treatments, including platinum-based chemotherapy, autologous stem cell transplant, and several immune checkpoint inhibitors, the remission has lasted over two years with no disease recurrence and detectable donor iNKT cells up to six months post-infusion. This case was published in Nature's Oncogene and highlights the therapy's potential in treating challenging solid tumors. Additionally, MiNK's phase II trial in gastric cancer has shown promising results, including significant tumor reduction and extended progression-free survival when agenT-797 was combined with Opdivo. Experts like Dr. Benjamin Garmezy have emphasized the profound potential of iNKT cell therapies to address cancers refractory to standard and experimental treatments. Overall, MiNK Therapeutics continues to advance clinical studies, supported by positive outcomes and growing investor interest reflected in share price surges and favorable analyst ratings.